Barriers to Buprenorphine Expansion in Ohio

A Time-Elapsed Qualitative Study

Todd Molfenter, Maureen Fitzgerald, Nora Jacobson, Dennis McCarty, Andrew Quanbeck, Mark Zehner

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Buprenorphine partial opioid agonist pharmacotherapy, a key treatment for opioid use disorders (OUDs), is underutilized in the United States. Qualitative interviews, conducted in 2012/2013 and repeated in 2015, identified systemic barriers to providing buprenorphine treatment in Ohio. A representative sample of Ohio’s Alcohol, Drug Abuse and Mental Health Services (ADAMHS) county boards (n = 18) was selected based on percentage of OUD admissions, density of buprenorphine prescribers, and county board area population. Boards reported that the barriers to the use of buprenorphine in 2012/2013 included (1) negative attitudes toward the use of buprenorphine among substance use disorder treatment providers; (2) a lack of prescribers; and (3) lack of funding. The 2015 interviews suggested that the lack of prescribers surpassed lack of funding as the main impediment to buprenorphine expansion. Negative provider attitudes were no longer problematic. Concerns about buprenorphine diversion, however, had emerged as a new barrier. This article offers recommendations for future policy efforts to overcome these barriers and expand the use of evidence-based opioid treatments. It highlights the need for payers and policymakers to increase the number of buprenorphine prescribers to make best use of funding available to fight the opioid epidemic.

Original languageEnglish (US)
JournalJournal of psychoactive drugs
DOIs
StatePublished - Jan 1 2019

Fingerprint

Buprenorphine
Opioid Analgesics
Substance-Related Disorders
Health Services Misuse
Interviews
Mental Health Services
Therapeutics
Alcoholism
Drug Therapy

Keywords

  • Buprenorphine
  • evidence-based practices
  • opioid use disorders
  • substance use disorders

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Psychology(all)

Cite this

Barriers to Buprenorphine Expansion in Ohio : A Time-Elapsed Qualitative Study. / Molfenter, Todd; Fitzgerald, Maureen; Jacobson, Nora; McCarty, Dennis; Quanbeck, Andrew; Zehner, Mark.

In: Journal of psychoactive drugs, 01.01.2019.

Research output: Contribution to journalArticle

Molfenter, Todd ; Fitzgerald, Maureen ; Jacobson, Nora ; McCarty, Dennis ; Quanbeck, Andrew ; Zehner, Mark. / Barriers to Buprenorphine Expansion in Ohio : A Time-Elapsed Qualitative Study. In: Journal of psychoactive drugs. 2019.
@article{7fdf101b872047a689bc56bb2d68f5a5,
title = "Barriers to Buprenorphine Expansion in Ohio: A Time-Elapsed Qualitative Study",
abstract = "Buprenorphine partial opioid agonist pharmacotherapy, a key treatment for opioid use disorders (OUDs), is underutilized in the United States. Qualitative interviews, conducted in 2012/2013 and repeated in 2015, identified systemic barriers to providing buprenorphine treatment in Ohio. A representative sample of Ohio’s Alcohol, Drug Abuse and Mental Health Services (ADAMHS) county boards (n = 18) was selected based on percentage of OUD admissions, density of buprenorphine prescribers, and county board area population. Boards reported that the barriers to the use of buprenorphine in 2012/2013 included (1) negative attitudes toward the use of buprenorphine among substance use disorder treatment providers; (2) a lack of prescribers; and (3) lack of funding. The 2015 interviews suggested that the lack of prescribers surpassed lack of funding as the main impediment to buprenorphine expansion. Negative provider attitudes were no longer problematic. Concerns about buprenorphine diversion, however, had emerged as a new barrier. This article offers recommendations for future policy efforts to overcome these barriers and expand the use of evidence-based opioid treatments. It highlights the need for payers and policymakers to increase the number of buprenorphine prescribers to make best use of funding available to fight the opioid epidemic.",
keywords = "Buprenorphine, evidence-based practices, opioid use disorders, substance use disorders",
author = "Todd Molfenter and Maureen Fitzgerald and Nora Jacobson and Dennis McCarty and Andrew Quanbeck and Mark Zehner",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/02791072.2019.1566583",
language = "English (US)",
journal = "Journal of Psychoactive Drugs",
issn = "0279-1072",
publisher = "Haight-Ashbury Publications",

}

TY - JOUR

T1 - Barriers to Buprenorphine Expansion in Ohio

T2 - A Time-Elapsed Qualitative Study

AU - Molfenter, Todd

AU - Fitzgerald, Maureen

AU - Jacobson, Nora

AU - McCarty, Dennis

AU - Quanbeck, Andrew

AU - Zehner, Mark

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Buprenorphine partial opioid agonist pharmacotherapy, a key treatment for opioid use disorders (OUDs), is underutilized in the United States. Qualitative interviews, conducted in 2012/2013 and repeated in 2015, identified systemic barriers to providing buprenorphine treatment in Ohio. A representative sample of Ohio’s Alcohol, Drug Abuse and Mental Health Services (ADAMHS) county boards (n = 18) was selected based on percentage of OUD admissions, density of buprenorphine prescribers, and county board area population. Boards reported that the barriers to the use of buprenorphine in 2012/2013 included (1) negative attitudes toward the use of buprenorphine among substance use disorder treatment providers; (2) a lack of prescribers; and (3) lack of funding. The 2015 interviews suggested that the lack of prescribers surpassed lack of funding as the main impediment to buprenorphine expansion. Negative provider attitudes were no longer problematic. Concerns about buprenorphine diversion, however, had emerged as a new barrier. This article offers recommendations for future policy efforts to overcome these barriers and expand the use of evidence-based opioid treatments. It highlights the need for payers and policymakers to increase the number of buprenorphine prescribers to make best use of funding available to fight the opioid epidemic.

AB - Buprenorphine partial opioid agonist pharmacotherapy, a key treatment for opioid use disorders (OUDs), is underutilized in the United States. Qualitative interviews, conducted in 2012/2013 and repeated in 2015, identified systemic barriers to providing buprenorphine treatment in Ohio. A representative sample of Ohio’s Alcohol, Drug Abuse and Mental Health Services (ADAMHS) county boards (n = 18) was selected based on percentage of OUD admissions, density of buprenorphine prescribers, and county board area population. Boards reported that the barriers to the use of buprenorphine in 2012/2013 included (1) negative attitudes toward the use of buprenorphine among substance use disorder treatment providers; (2) a lack of prescribers; and (3) lack of funding. The 2015 interviews suggested that the lack of prescribers surpassed lack of funding as the main impediment to buprenorphine expansion. Negative provider attitudes were no longer problematic. Concerns about buprenorphine diversion, however, had emerged as a new barrier. This article offers recommendations for future policy efforts to overcome these barriers and expand the use of evidence-based opioid treatments. It highlights the need for payers and policymakers to increase the number of buprenorphine prescribers to make best use of funding available to fight the opioid epidemic.

KW - Buprenorphine

KW - evidence-based practices

KW - opioid use disorders

KW - substance use disorders

UR - http://www.scopus.com/inward/record.url?scp=85061280016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061280016&partnerID=8YFLogxK

U2 - 10.1080/02791072.2019.1566583

DO - 10.1080/02791072.2019.1566583

M3 - Article

JO - Journal of Psychoactive Drugs

JF - Journal of Psychoactive Drugs

SN - 0279-1072

ER -